France, Feb. 27 -- Lenacapavir, known as LEN, is a long-acting injectable administered once every six months. Named 'Breakthrough of the Year' by Science magazine in 2024, the drug is injected subcutaneously, just below the skin, in he lower abdomen or thighs.

The injection will be administered twice a year and offered free of charge to eligible individuals at selected public health facilities in priority counties. Pregnant and breastfeeding mothers can also use he drug safely.

The government has also put in place mechanisms to track side effects.

World AIDS Day highlights major innovations amid decline in global funding

"Today is a moment of hope for thousands of Kenyan families," Health Minister Aden Duale said on Thursday during th...